2nd March, 2020: Following a successful global search by The RSA Group, Cantargia announced last week the appointment of Dr Ignacio Garcia-Ribas as Chief Medical Officer.
Cantargia is a biotechnology company developing antibody-based treatments for life-threatening diseases. Dr Garcia-Ribas will have a key role in the Company’s main project, the advancement of the CAN04 antibody, currently in phase IIa clinical development for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC).
Dr Garcia-Ribas brings over 15 years’ experience in the pharma industry to the role, having worked extensively in the oncology early drug development sector. Most recently he held the position of Senior Medical Director at Takeda and was the Global Clinical Lead for several of the Company’s Phase I and II programs. Prior to this he was Senior Medical Director of Sanofi’s early oncology development group and was part of the Early Development Unit in Eli Liliy.
Thomas Schleimer, Managing Partner at The RSA Group, commented, “The appointment of Dr Garcia-Ribas at Cantargia is the result of an extensive global search and the careful due diligence by the RSA Group team. Being a boutique search consultancy means we can often go deeper into the market and have fewer restrictions such as ‘off limits’. This excellent outcome demonstrates the team’s ability to access the best candidates in their field. ”
Göran Forsberg, Chief Executive Officer at Cantargia, said, “we are thrilled to have Ignacio join the Cantargia team. His track record in oncology early drug development will make him a great asset. We are grateful to The RSA Group for their excellent advice and for their help in establishing what the Company needed from this role. We are so pleased to have attracted a candidate of Ignacio’s calibre and experience.”